4:30 AM
Feb 20, 2019
 |  BC Extra  |  Financial News

BiomX raises $32M series B to bring first two therapies to clinic

Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday that will take its lead candidate, acne therapy BX001, into the clinic within the next few months. The company said the round will also provide resources to start clinical testing of its inflammatory bowel disease (IBD) program BX002 toward the end of 2020.

CEO Jonathan Solomon told BioCentury that...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >